Page 1

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

In Re: CELEXA AND

LEXAPRO MARKETING AND

MDL No. 2007

Master Docket No.

09-MD-2067 (NMG) SALES PRACTICES

U9-MD-200.

Case No. 13 CV 13113

PAINTERS AND ALLIED TRADES DISTRICT COUNCIL 82 HEALTH CARE FUND, A THIRD-PARTY HEALTHCARE PAYOR FUND

Plaintiffs

FOREST PHARMACEUTICALS, INC. and

FOREST LABORATORIES, INC.

Defendants.

-----x

In Re: CELEXA AND MDL No. 2067

LEXAPRO MARKETING AND Master Docket No. SALES PRACTICES 09-MD-2067 (NMG)
LITIGATION Case No. 14 CV 13848

DELANA S. KIOSSOVISKI and RENEE RAMIREZ, on behalf of themselves and all others similarly situated,

Plaintiffs,

v.

FOREST PHARMACEUTICALS, INC. and FOREST LABORATORIES, INC. Defendants.

VIDEOTAPED DEPOSITION OF GERARD J. AZZARI New York, New York July 21, 2016

Reported by:

MARY F. BOWMAN, RPR, CRR

Gerard J. Azzari

```
Page 236
            Q. So I am going to ask you again,
 1
        based on your knowledge and experience
 2
        between 2002 and 2009, did Forest sales
3
        representatives engage in off-label
 4
        promotion of Lexapro for use in pediatric
5
6
        patients?
7
                  MS. KIEHN: Objection.
8
            A. Could I talk to counsel about
9
        this question?
10
            Q. Not while it's pending. I'm
11
        asking you for your answer based on your
12
        knowledge and experience.
13
                  MS. KIEHN: Right. If the only
            basis for your knowledge is
14
            communications with counsel, then you
15
            shouldn't respond. But he is asking
16
17
            based on your personal knowledge, do
18
            you know whether.
19
            Q. Let me state it again, because I
        want you to understand what I am asking
20
21
        you.
22
            A. OK, yes, yes, yes.
23
            Q. Based on your knowledge and
24
        experience and your years at Forest,
```

Gerard J. Azzari

```
Page 237
1
        between 2002 and 2009, did Forest sales
        representatives engage in off-label
 2
        promotion of Lexapro for use in pediatric
 3
 4
        patients?
5
            A. I have knowledge that
        representatives may have presented Celexa
6
7
        or Lexapro inappropriately.
            Q. Between 2002 and 2009?
8
9
            A. Yes.
10
            Q. And you know that, you have
        knowledge of that related to Lexapro,
11
12
        correct?
13
                  MS. KIEHN: Objection.
14
            A. Yes.
15
            Q. And that's based on your
        knowledge that child specialists were on
16
17
        Lexapro call panels between 2002 and 2009,
18
        correct?
19
                  MS. KIEHN: Objection.
20
            A.
                  No. My commentary was that
21
        individuals may have inappropriately
22
        presented Celexa or Lexapro to physicians.
                  Well, you know that there were
23
            Q.
24
         child specialists included on Lexapro call
```